Literature DB >> 23264855

TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression.

Jason St John1, Katelyn Powell, M Katie Conley-Lacomb, Sreenivasa R Chinni.   

Abstract

TMPRSS2-Ets gene fusions were identified in prostate cancers where the promoter of transmembrane protease, serine 2 (TMPRSS2) fused with coding sequence of the erythroblastosis virus E26 (Ets) gene family members. TMPRSS2 is an androgen responsive transmembrane serine protease. Ets family members are oncogenic transcription factors that contain a highly conserved Ets DNA binding domain and an N-terminal regulatory domain.Fusion of these gene results in androgen dependent transcription of Ets factor in prostate tumor cells. The ERG is the most common fusion partner with TMPRSS2 promoter in prostate cancer patients. The high prevalence of these gene fusions, in particular TMPRSS2-ERG, makes them attractive as potential diagnostic and prognostic indicators, as well as making them a potential target for tailored therapies.This review focuses on the clinical and biological significance of TMPRSS2-ERG fusions and their role in PC development and progression.

Entities:  

Year:  2012        PMID： 23264855      PMCID： PMC3527835          DOI： 10.4172/1948-5956.1000119

Source DB:  PubMed          Journal:  J Cancer Sci Ther


  75 in total

1.  TMPRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer.

Authors:  Elisabetta Baldi; Lorella Bonaccorsi; Gabriella Nesi; Sergio Serni; Gianni Forti; Lucio Luzzatto
Journal:  Arch Pathol Lab Med       Date:  2010-07       Impact factor: 5.534

2.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

3.  The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner.

Authors:  J P Basuyaux; E Ferreira; D Stéhelin; G Butticè
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

4.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

5.  Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Authors:  Bungo Furusato; Chun-Ling Gao; Lakshmi Ravindranath; Yongmei Chen; Jennifer Cullen; David G McLeod; Albert Dobi; Shiv Srivastava; Gyorgy Petrovics; Isabell A Sesterhenn
Journal:  Mod Pathol       Date:  2007-12-07       Impact factor: 7.842

6.  Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Authors:  Karin G Hermans; Joost L Boormans; Delila Gasi; Geert J H L van Leenders; Guido Jenster; Paul C M S Verhagen; Jan Trapman
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

7.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

8.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

9.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.

Authors:  Jiangling J Tu; Stephen Rohan; Jean Kao; Naoki Kitabayashi; Susan Mathew; Yao-Tseng Chen
Journal:  Mod Pathol       Date:  2007-07-13       Impact factor: 7.842

10.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701
View more
  34 in total

1.  Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.

Authors:  Jintang He; Xuefei Sun; Tujin Shi; Athena A Schepmoes; Thomas L Fillmore; Vladislav A Petyuk; Fang Xie; Rui Zhao; Marina A Gritsenko; Feng Yang; Naoki Kitabayashi; Sung-Suk Chae; Mark A Rubin; Javed Siddiqui; John T Wei; Arul M Chinnaiyan; Wei-Jun Qian; Richard D Smith; Jacob Kagan; Sudhir Srivastava; Karin D Rodland; Tao Liu; David G Camp
Journal:  Mol Oncol       Date:  2014-02-21       Impact factor: 6.603

2.  Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia.

Authors:  S Velaeti; E Dimitriadis; K Kontogianni-Katsarou; A Savvani; E Sdrolia; G Pantazi; S Stefanakis; T Trangas; N Pandis; K Petraki
Journal:  Tumour Biol       Date:  2014-06-25

3.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.

Authors:  Stephen J Murphy; Marie-Christine Aubry; Faye R Harris; Geoffrey C Halling; Sarah H Johnson; Simone Terra; Travis M Drucker; Michael K Asiedu; Benjamin R Kipp; Eunhee S Yi; Tobias Peikert; Ping Yang; George Vasmatzis; Dennis A Wigle
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

Review 4.  Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.

Authors:  M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

5.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

6.  Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element.

Authors:  Liesbeth Clinckemalie; Lien Spans; Vanessa Dubois; Michaël Laurent; Christine Helsen; Steven Joniau; Frank Claessens
Journal:  Mol Endocrinol       Date:  2013-10-09

7.  Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.

Authors:  Stephen J Murphy; Dennis A Wigle; Joema Felipe Lima; Faye R Harris; Sarah H Johnson; Geoffrey Halling; Michael K Asiedu; Charlie T Seto; Simone Terra; Farhad Kosari; Tobias Peikert; Ping Yang; Marie-Christine Aubry; George Vasmatzis
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

8.  Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.

Authors:  Yinhui Yang; Alexandra M Blee; Dejie Wang; Jian An; Yunqian Pan; Yuqian Yan; Tao Ma; Yundong He; Joseph Dugdale; Xiaonan Hou; Jun Zhang; S John Weroha; Wei-Guo Zhu; Y Alan Wang; Ronald A DePinho; Wanhai Xu; Haojie Huang
Journal:  Cancer Res       Date:  2017-10-06       Impact factor: 12.701

9.  A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.

Authors:  M J Donovan; M Noerholm; S Bentink; S Belzer; J Skog; V O'Neill; J S Cochran; G A Brown
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-09-08       Impact factor: 5.554

Review 10.  miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.

Authors:  Clayton Yates; Mark D Long; Moray J Campbell; Lara Sucheston-Campbell
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.